Understanding how certain antibodies can worsen dengue disease
Mechanisms of Antibody-Dependent Enhancement of Dengue Disease
This study is looking into how certain antibodies might actually make dengue disease worse instead of helping, and it's aimed at people living in areas like Cambodia where dengue is a big problem, to find out more about how this happens and what we can do about it.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rockefeller University NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10870026 on NIH RePORTER |
What this research studies
This research investigates the role of specific antibodies in increasing the severity of dengue disease, rather than providing protection. It focuses on how pre-existing antibodies can lead to a higher risk of symptomatic dengue, which can include severe complications. By using in vitro cellular assays, the study aims to uncover the mechanisms behind antibody-dependent enhancement (ADE) of dengue virus infection. The research is conducted in collaboration with the Institute Pasteur in Cambodia, a region heavily affected by dengue, to better understand the disease's pathophysiology and potential therapeutic approaches.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals living in dengue-endemic areas, particularly those with a history of dengue infection.
Not a fit: Patients who have never been exposed to dengue virus or those living in non-endemic regions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments or vaccines for dengue, reducing the risk of severe disease in affected populations.
How similar studies have performed: Previous studies have shown that understanding antibody interactions can lead to breakthroughs in managing viral infections, suggesting potential for success in this area.
Where this research is happening
New York, United States
- Rockefeller University — New York, United States (Active)
Researchers
- Principal investigator: Bournazos, Stylianos — Rockefeller University
- Study coordinator: Bournazos, Stylianos
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.